Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag 3.6 million Medicare enrollees may become eligible for Wegovy, an anti-obesity drug, with potential $3B annual cost.

flag 3.6 million Medicare enrollees may become eligible for coverage of Wegovy, an anti-obesity drug, according to a KFF analysis. flag The FDA approved Wegovy for reducing cardiovascular disease risk in overweight or obese adults without diabetes. flag However, Medicare's budget may be strained as it could cost nearly $3 billion annually and contribute to higher Part D premiums for all beneficiaries.

8 Articles

Further Reading